Clinical trial

Randomized, Blind and Positive Control Design: a Phase III Clinical Trial to Evaluate the Consistency Between Batches of 5 Doses of Freeze-dried Rabies Vaccine (Vero Cell) and the Immunogenicity and Safety of 4 Doses of Vaccine (1-1-1-1)

Name
ZY202106001
Description
To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according to five dose immunization procedures.
Trial arms
Trial start
2022-06-18
Estimated PCD
2024-05-30
Trial end
2024-12-30
Phase
Early phase I
Treatment
immunization procedures
The subjects were vaccinated with rabies vaccine according to different immunization procedures
Arms:
4 doses, 5 doses
Size
2100
Primary endpoint
Positive conversion rate of 14 days
6 months
Antibody Geometric Mean Titer (GMT) of 14 days
6 months
Positive conversion rate of 42 days
6 months
Advertise Events (AE) incidence within 1 month
6 months
Serious Adverse Events (SAE) incidence within 6 months
12 months
Eligibility criteria
Inclusion Criteria: * People aged 10-60; * Body temperature on the day of enrollment\<37.3℃ (axillary temperature) Exclusion Criteria: * Have a history of rabies vaccine immunization or use of rabies virus passive immunization agents; * People with congenital or acquired immunodeficiency or other autoimmune diseases; * Female urine pregnancy test is positive, or during pregnancy and lactation, or she has a birth plan during the study period;
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 2100, 'type': 'ESTIMATED'}}
Updated at
2024-03-13

1 organization

1 product

2 indications

Indication
Rabies Human
Indication
Antibody